Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase–polymerase chain reaction or flow cytometry. MRD is the strongest predictor of relapse in ALL. In this...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Gökbuget, Nicola, Dombret, Hervé, Bonifacio, Massimiliano, Reichle, Albrecht, Graux, Carlos, Faul, Christoph, Diedrich, Helmut, Topp, Max S., Brüggemann, Monika, Horst, Heinz-August, Havelange, Violaine, Stieglmaier, Julia, Wessels, Hendrik, Haddad, Vincent, Benjamin, Jonathan E., Zugmaier, Gerhard, Nagorsen, Dirk, Bargou, Ralf C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2018
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6027091/
https://ncbi.nlm.nih.gov/pubmed/29358182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-08-798322
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller